Elsevier

Clinical Therapeutics

Volume 24, Issue 4, April 2002, Pages 565-573
Clinical Therapeutics

Risk factor analysis of hypersensitivity reactions to abacavir

https://doi.org/10.1016/S0149-2918(02)85132-3Get rights and content

Abstract

Background: A hypersensitivity reaction to abacavir has been known to occur in ∼4% of patients treated with the drug.

Objective: The goal of this study was to determine risk factors associated with the development of hypersensitivity reactions to abacavir.

Methods: We constructed an analysis population from all protocols conducted by GlaxoSmithKline that involved at least 24 weeks of abacavir exposure with a quality-assured or validated clinical database by June 30, 2000. Demographic, clinical, and laboratory characteristics of patients who developed a hypersensitivity reaction to abacavir were compared with those of patients who did not. Univariate and multivariate logistic regression models were fit to understand the predictive ability of each potential risk factor. Odds ratios (ORs) and 95% Wald CIs were computed.

Results: A total of 5332 patients exposed to abacavir were included in this analysis; 197 cases of hypersensitivity reaction were reported (3.7%). In univariate models, several associations were noted, but most subgroups produced rates within the expected range of 3% to 6%. The multivariate model using all demographic data available (Model 1) indicated that the risk of hypersensivitiy reaction among black patients (3% hypersensitivity reaction) was lower (OR = 0.59; 95% CI, 0.38–0.91) compared with other ethnic groups. In addition, a lower rate of hypersensitivity reaction was observed in patients who received previous therapy for HIV-1 infection with other antiretroviral agents (3% hypersensitivity reaction) compared with those receiving therapy for the first time (OR = 0.58; 95% CI, 0.44–0.78).

Conclusions: The only characteristics identified as prognostic factors for hypersensitivity reaction to abacavir were antiretroviral treatment status (ie, treatment experience) and black race, each resulting in a lower rate compared with the expected incidence.

References (8)

There are more references available in the full text version of this article.

Cited by (113)

  • HIV pharmacogenetics and pharmacogenomics: From bench to bedside

    2019, Genomic and Precision Medicine: Infectious and Inflammatory Disease
  • Human Immunodeficiency Virus Organ Transplantation

    2018, Infectious Disease Clinics of North America
    Citation Excerpt :

    Both are associated with high barriers to HIV drug resistance. Abacavir has a known genetic association with a hypersensitivity reaction84 that is predicted by testing for the HLA-B5701 marker.85 Abacavir has also been linked to adverse cardiac events in some studies but not others.86

  • Incorporating pharmacogenomics in drug development: A perspective from industry

    2018, Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation
  • Validation of two commercial real-time PCR assays for rapid screening of the HLA-B*57:01 allele in the HIV clinical laboratory

    2016, Journal of Virological Methods
    Citation Excerpt :

    In such cases, death may occur, if dosing is continued or if ABC is re-challenged (Hughes et al., 2008). Genetic research has shown that HSR to ABC in Caucasian HIV-1 infected patients was significantly associated with carriage of the HLA-B*57:01 allele (Symonds et al., 2002; Mallal et al., 2002). The PREDICT-1 trial demonstrated that prospective screening of HLA-B*57:01 prevented entirely the occurrence of ABC HSR among HIV-1 infected Caucasians in Europe and in Australia (Mallal et al., 2008).

View all citing articles on Scopus
View full text